elsubrutinib
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 25, 2018 (NCT03682705)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Jak1 proteinINHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase BTKINHIBITOR
Tyrosine-protein kinase BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1- Mol. weight
- 297.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594348 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04451772 | Phase 2 | Jul 17, 2020 | AbbVie |
| NCT03978520 | Phase 2 | Jul 19, 2019 | AbbVie |
| NCT03823378 | Phase 2 | May 13, 2019 | AbbVie |
| NCT03682705 | Phase 2 | Sep 25, 2018 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 1 | 2018 |
1 organizations
Page 1 / 1